schizophrenia – Page 2

Clozapine and Infection Risk in Schizophrenia: Insights from a Hong Kong Population Study

By MedXY 08/22/2025

This study reveals an increased risk of infections among schizophrenia patients treated with clozapine compared to olanzapine, highlighting the need for vigilant infection monitoring and preventive care.

Clinical Updates news Psychiatry Specialties

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY 08/03/2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

AI Clinical Updates news Psychiatry Specialties

Comparative Analysis of Virtual Reality Therapies for Psychotic Symptoms: Auditory Hallucinations vs. Persecutory Delusions

By MedXY 08/02/2025

Two randomized controlled trials evaluated immersive VR therapies targeting auditory verbal hallucinations and persecutory delusions in schizophrenia and psychosis, revealing modest benefits for hallucinations but no superior effect for cognitive VR therapy in delusions.